Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.


Listen to the latest hemonc news from international experts

Key updates on CAR-T & cellular therapy for AML

Acute myeloid leukemia (AML) is the most common type of leukemia in adults and is highly heterogenous. AML is typically treated with chemotherapy and allogeneic stem cell transplantation, however not all patients are eligible or able to tolerate these regimens, and many patients will experience relapse. Chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated promising results in the treatment of B-cell lymphomas and is now being explored in AML.

In this podcast, Saar Gill, MD, PhD, of the Perelman School of Medicines, PA, Richard Aplenc, MD, PhD, MSCE, of the Children’s Hospital of Philadelphia, PA, Marion Subklewe, MD, of the LMU Hospital Munich in Germany, and Rizwan Romee, MD, of the Dana-Farber Cancer Institute, MA, discuss the latest data from clinical trials, comparing CAR-T therapy to other immunotherapeutic approaches, and outlining the potential role of CAR-NK cells in AML treatment.

Date: 17th May 2021

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter